A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: A Southwest Oncology Group Study

To estimate the probability of response when intravesical bacille Calmette-Guérin (BCG) is given in combination with oral bropirimine for bladder carcinoma in situ, and to evaluate toxicity when the 2 agents are combined. A total of 51 patients with histologic evidence of carcinoma in situ and no pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Urologic oncology 2005-11, Vol.23 (6), p.386-389
Hauptverfasser:	Sarosdy, Michael F., Tangen, Catherine M., Weiss, Geoffrey R., Nestok, Blake R., Benson, Mitchell C., Schellhammer, Paul F., Sagalowsky, Arthur I., Wood, David P., Crawford, E. David
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over BCG Vaccine - therapeutic use Biological and medical sciences Bladder cancer Bropirimine Carcinoma in Situ - drug therapy Carcinoma in Situ - pathology Cytosine - administration & dosage Cytosine - analogs & derivatives Cytosine - pharmacology Disease Progression Humans Immunotherapy Medical Oncology Medical sciences Middle Aged Nephrology. Urinary tract diseases Survival Rate Tumors Tumors of the urinary system United States Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!